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Human tissue legislation in South 
Africa
Concerning human tissue legislation, the law has traditionally 
struggled to match the pace of scientific and technological advances.1 
In this respect, the National Health Act2 (NHA) assented to by the 
President on 18 July 2004 came into force on 2 May 2005. At that 
time matters pertaining to human tissues were legislated under the 
Human Tissue Act3 (HTA), since chapter 8 of the NHA, ‘Control of 
use of blood, blood products, tissue and gametes in humans’, had not 
been enacted. At least seven identifiable areas are covered by chapter 
8 of the NHA: blood and blood products; assisted reproductive 
technology; cell-based therapy; transplantation; DNA and genetic 
services; tissue banks; and examination, allocation and disposal of 
human bodies and tissues.
Although chapter 8 of the NHA and the HTA that preceded it deal 
specifically with human tissues,4 legislation pertaining to human 
tissues is also governed by (without being limited to) the Medicines 
and Related Substances Control Act5 (Medicines Act), the Children’s 
Act,6 the Inquest Act7 and the Consumer Protection Act.8
The regulatory vacuum: cell-based 
therapy, a case in point
As identified previously, ‘the HTA was drafted at a time when 
many of the cutting edge scientific and medical practices, which 
have become part of routine medical practice today, were still in 
their infancy or barely envisaged. This includes for example much 
of assisted reproductive technology, cell-based therapy and tissue 
banks. Many of the advances in blood transfusion, transplantation 
and genetic services which occurred subsequent to that time were 
likewise not provided for in the HTA.’9
The previous suggestion that chapter 8 of the NHA is the major 
part of the legislation in South Africa that deals with the issue of cell-
based therapy10 was predicated upon the recognition that this field 
involves several diverse but interrelated entities. This includes but is 
not limited to reproductive and therapeutic cloning, embryonic stem 
cells, tissue (and specifically stem cell) banks, tissue/organ trafficking, 
and the notion of profit (or lack thereof) when dealing with human 
tissues. It has been suggested that the Medicines Act ‘is the primary 
legislation that regulates cell-based therapy’, and that ‘new stem cell 
therapies would be subject to the same safety, efficacy and quality 
requirements as any other new medicine’.4 While this is correct from 
the perspective of a ‘new medicine’, the Medicines Act does not deal 
with many other matters pertaining to stem cells referred to above, 
most of which are covered by the recently promulgated sections 
of chapter 8. Failure to recognise this diversity reflects a lack of 
understanding of the complexity of cell biology in general, and stem 
cell biology in particular. The most vulnerable people are frequently 
targeted in settings in which untested and costly so-called stem cell 
treatments are utilised, and consequently need to be protected.11 It is 
likely that the Consumer Protection Act, in which the strict liability 
principle places the responsibility on any identifiable component/
person in the supply chain, will play an important role in protecting 
vulnerable patients.12
Enactment of chapter 8 of the NHA 
and regulations thereto
All the sections of chapter 8 of the NHA have now been enacted and 
the HTA has been repealed. Thus, section 53 of the NHA came into 
force on 30 June 200813 and sections 55, 56 and 68 on 17 May 2011,14 
the remaining sections 54 and 57 - 67 being enacted on 1 March 
2012.15 In addition, several sets of regulations that are pertinent to 
chapter 8 were published on 2 March 2012.16
While the promulgation of chapter 8 and regulations thereto might 
be a welcome step towards partial relief from the regulatory vacuum, 
several important gaps still exist and several newly introduced 
inaccuracies have added further complexity to the situation. A few 
examples follow.
Although the definition of ‘stem cells’ as ‘cells that have both the 
capacity to self-regenerate as well as to differentiate into mature 
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Human tissue legislation is complex. An exhaustive understanding 
of the law, thorough understanding of human tissue biology and 
pathophysiology and an appreciation of the diversity of the areas 
covered in this field, is critical. The importance of interdisciplinary 
co-operation in the drafting, interpretation and implementation 
of legislation in this area cannot be overemphasised. Several 
factors underscore this, including the complexity and volume of 
the information involved, rapid advances in science, reciprocal 
dependence of the law and science on one another for relevance 
and accuracy, and above all the need to ensure that the patient’s 
well-being and safety are not compromised. The development of 
technology also must be encouraged in a non-obstructive legislative 
setting.
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specialised cells’ is accurate and consistent in three of the regulations 
published on 2 March 2012,17-19 different definitions are given for ‘cell’ 
in two of the regulations published on the same date. Thus, while 
the definition of a cell as ‘the smallest structural and functional unit 
of an organism, consisting of cytoplasm and a nucleus enclosed in a 
membrane in living things’17 is scientifically more accurate, it would 
be important to determine how the definition of a cell as ‘a small 
container of chemical and water wrapped in a membrane’20 would 
hold up under legal scrutiny.
In the recently promulgated section 57 of chapter 8, ‘Prohibition 
of reproductive cloning of human beings’, therapeutic cloning is 
defined as ‘the manipulation of genetic material from either adult, 
zygotic or embryonic cells in order to alter, for therapeutic purposes, 
the function of cells or tissues’.21 The universally accepted definition 
of therapeutic cloning is ‘somatic cell nuclear transfer’, which could 
conceivably be embraced by the definition currently in chapter 8. 
However, the definition of therapeutic cloning in section 57 is far 
broader than somatic cell nuclear transfer, and ironically is closer in 
part to the definition of the procedure required to produce genetically 
modified and transgenic cells or organisms.
The definition of transgenic cells is given as ‘cells derived from a 
species other than human’.17 This is incorrect. The accepted definition 
of cells derived from other species is xenogeneic. This fundamental 
error could have important consequences, particularly in South 
Africa where there is currently a rapid escalation in litigation for 
medical malpractice.22
Much effort will now be required to correct these inadequacies, 
which involve the Act (chapter 8) and many of the regulations. 
Revision of the regulations is less onerous, as it requires the approval 
of the Minister of Health. Revision of the Act is more complex, and 
will require a passage through Cabinet and Parliament. Chapter 8 
will apparently only be revised with revision of the entire Act, which 
may take some time. In the meantime we must live and work with the 
legislation at hand, and where this is lacking or inaccurate, be guided 
by international best practice.
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